Ken Griffin Bei Gene, Ltd. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,900 shares of BGNE stock, worth $707,315. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,900

Previous 6,500 24.62%

Holding current value

$707,315

Previous $1.17 Million 34.64%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $1.66 Million - $2.13 Million	-11,722 Reduced 99.16%	99 $15,000
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $1.16 Million - $1.47 Million	7,284 Added 160.55%	11,821 $2.13 Million
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $5.73 Million - $7.17 Million	-31,854 Reduced 87.53%	4,537 $816,000
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $3.96 Million - $5.92 Million	22,207 Added 156.56%	36,391 $6.49 Million
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $5.8 Million - $7.39 Million	-26,910 Reduced 65.48%	14,184 $3.06 Million

Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $1.79 Million - $3.27 Million	14,263 Added 53.16%	41,094 $9.04 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $1.98 Million - $3.04 Million	-15,044 Reduced 35.93%	26,831 $3.62 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $4.67 Million - $8.33 Million	38,567 Added 1165.87%	41,875 $6.78 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $200,732 - $369,297	1,370 Added 70.69%	3,308 $624,000
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $7.57 Million - $11.9 Million	-30,439 Reduced 94.01%	1,938 $525,000
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $6.32 Million - $10.2 Million	25,332 Added 359.57%	32,377 $11.8 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $661,615 - $829,442	2,260 Added 47.23%	7,045 $2.42 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $2.37 Million - $3.48 Million	-9,103 Reduced 65.55%	4,785 $1.67 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $176,384 - $252,338	-797 Reduced 5.43%	13,888 $3.59 Million
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $2.44 Million - $3.69 Million	12,888 Added 717.2%	14,685 $4.21 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $1.16 Million - $1.84 Million	-9,398 Reduced 83.95%	1,797 $339,000
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $1.24 Million - $1.76 Million	-10,180 Reduced 47.63%	11,195 $1.38 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $33,228 - $59,793	-287 Reduced 1.32%	21,375 $3.54 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $918,075 - $1.18 Million	8,054 Added 59.19%	21,662 $2.69 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $414,271 - $512,122	-3,373 Reduced 19.86%	13,608 $0
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $1.2 Million - $1.96 Million	11,168 Added 192.12%	16,981 $2.38 Million
Q3 2018 Nov 13, 2018	SELL	$152.62 - $189.66 $2.25 Million - $2.8 Million	-14,765 Reduced 71.75%	5,813 $0
Q2 2018 Aug 10, 2018	BUY	$152.5 - $216.77 $3.14 Million - $4.46 Million	20,578 New	20,578 $0

Others Institutions Holding BGNE

# of Institutions

216

Shares Held

45.1M

Call Options Held

76.5K

Put Options Held

72.3K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $15B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account